Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma

Stock Information for Replimune Group Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Replimune Group Inc.

Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update
Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Replimune Appoints Dieter Weinand as Chairman and Paolo Pucci to the Board of Directors
Replimune to Present at the Piper Jaffray 31st Annual Healthcare Conference
Replimune Provides Update on RP1 Clinical Development Program in Cutaneous Squamous Cell Carcinoma

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.